A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer

[1]  M. Kahn,et al.  β-Catenin signaling is a critical event in ErbB2-mediated mammary tumor progression. , 2013, Cancer research.

[2]  Jason I. Herschkowitz,et al.  Met synergizes with p53 loss to induce mammary tumors that possess features of claudin-low breast cancer , 2013, Proceedings of the National Academy of Sciences.

[3]  E. Andrechek,et al.  A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer , 2013, Oncogene.

[4]  A. El‐Naggar,et al.  p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. , 2012, Cancer cell.

[5]  J. Nevins,et al.  Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence , 2012, Oncogene.

[6]  D. Giri,et al.  Activation Status of Wnt/ß-Catenin Signaling in Normal and Neoplastic Breast Tissues: Relationship to HER2/neu Expression in Human and Mouse , 2012, PloS one.

[7]  A. Roopra,et al.  A Phenotypic Mouse Model of Basaloid Breast Tumors , 2012, PloS one.

[8]  Michael C. Rusch,et al.  Integrated cross-species transcriptional network analysis of metastatic susceptibility , 2012, Proceedings of the National Academy of Sciences.

[9]  J. Livingstone,et al.  Transgenic IGF-IR overexpression induces mammary tumors with basal-like characteristics, whereas IGF-IR-independent mammary tumors express a claudin-low gene signature , 2011, Oncogene.

[10]  R. Cardiff,et al.  STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomas , 2012, Breast Cancer Research.

[11]  F. Gu,et al.  Notch1 is involved in migration and invasion of human breast cancer cells. , 2011, Oncology reports.

[12]  Mark T. W. Ebbert,et al.  Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes , 2011, Nature Medicine.

[13]  Min Zhu,et al.  Integrated miRNA and mRNA expression profiling of mouse mammary tumor models identifies miRNA signatures associated with mammary tumor lineage , 2011, Genome Biology.

[14]  Jason I. Herschkowitz,et al.  Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells , 2011, Proceedings of the National Academy of Sciences.

[15]  S. Hilsenbeck,et al.  Keratin 6a marks mammary bipotential progenitor cells that can give rise to a unique tumor model resembling human normal-like breast cancer , 2011, Oncogene.

[16]  Yan Liu,et al.  Proteome and transcriptome profiles of a Her2/Neu‐driven mouse model of breast cancer , 2011, Proteomics. Clinical applications.

[17]  E. Andrechek,et al.  Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors. , 2011, Cancer research.

[18]  R. Glazer,et al.  PPARδ Activation Acts Cooperatively with 3-Phosphoinositide-Dependent Protein Kinase-1 to Enhance Mammary Tumorigenesis , 2011, PloS one.

[19]  E. A. Fry,et al.  Transgenic and Knockout Mice Models to Reveal the Functions of Tumor Suppressor Genes , 2011, Clinical Medicine Insights. Oncology.

[20]  Peter M Schlag,et al.  Identification of early molecular markers for breast cancer , 2011, Molecular Cancer.

[21]  T. Pawson,et al.  Receptor tyrosine kinase signaling favors a protumorigenic state in breast cancer cells by inhibiting the adaptive immune response. , 2010, Cancer research.

[22]  Jason I. Herschkowitz,et al.  Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer , 2010, Breast Cancer Research.

[23]  A. Borowsky,et al.  Pilot study on the effects of dietary conjugated linoleic acid on tumorigenesis and gene expression in PyMT transgenic mice. , 2010, Carcinogenesis.

[24]  Jason I. Herschkowitz,et al.  Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. , 2010, The Journal of clinical investigation.

[25]  Jason I. Herschkowitz,et al.  Fibroblast growth factor receptor signaling dramatically accelerates tumorigenesis and enhances oncoprotein translation in the mouse mammary tumor virus-Wnt-1 mouse model of breast cancer. , 2010, Cancer research.

[26]  Elgene Lim,et al.  Open Access Research Article Transcriptome Analyses of Mouse and Human Mammary Cell Subpopulations Reveal Multiple Conserved Genes and Pathways , 2022 .

[27]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[28]  Jeffrey T. Chang,et al.  Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential , 2009, Proceedings of the National Academy of Sciences.

[29]  M. J. van de Vijver,et al.  The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis , 2009, Proceedings of the National Academy of Sciences.

[30]  B. Schaffhausen,et al.  Lessons in Signaling and Tumorigenesis from Polyomavirus Middle T Antigen , 2009, Microbiology and Molecular Biology Reviews.

[31]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[32]  R. Cardiff,et al.  Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[33]  Yiling Lu,et al.  Expression of autotaxin and lysophosphatidic acid receptors increases mammary tumorigenesis, invasion, and metastases. , 2009, Cancer cell.

[34]  R. Cardiff,et al.  PTEN Deficiency in a Luminal ErbB-2 Mouse Model Results in Dramatic Acceleration of Mammary Tumorigenesis and Metastasis* , 2009, The Journal of Biological Chemistry.

[35]  R. Kucherlapati,et al.  Genetic Mechanisms in Apc-Mediated Mammary Tumorigenesis , 2009, PLoS genetics.

[36]  M. West,et al.  High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics , 2008, Journal of the American Statistical Association.

[37]  Daniel Medina,et al.  Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. , 2008, Cancer research.

[38]  R. Cardiff,et al.  Phosphatase and tensin homologue deleted on chromosome 10 deficiency accelerates tumor induction in a mouse model of ErbB-2 mammary tumorigenesis. , 2008, Cancer research.

[39]  Gavin Sherlock,et al.  Isolation and Molecular Characterization of Cancer Stem Cells in MMTV‐Wnt‐1 Murine Breast Tumors , 2008, Stem cells.

[40]  Jason I. Herschkowitz,et al.  Characterization of mammary tumors from Brg1 heterozygous mice , 2008, Oncogene.

[41]  Jason I. Herschkowitz,et al.  ETV6-NTRK3 fusion oncogene initiates breast cancer from committed mammary progenitors via activation of AP1 complex. , 2007, Cancer cell.

[42]  Stephen T. Brown,et al.  An EGR2/CITED1 Transcription Factor Complex and the 14-3-3σ Tumor Suppressor Are Involved in Regulating ErbB2 Expression in a Transgenic-Mouse Model of Human Breast Cancer , 2007, Molecular and Cellular Biology.

[43]  R. Cardiff,et al.  Distinct ErbB-2 coupled signaling pathways promote mammary tumors with unique pathologic and transcriptional profiles. , 2007, Cancer research.

[44]  I. Petersen,et al.  Comparison of gene expression data from human and mouse breast cancers: Identification of a conserved breast tumor gene set , 2007, International journal of cancer.

[45]  P. Sorensen,et al.  Cellular transformation and activation of the phosphoinositide-3-kinase-Akt cascade by the ETV6-NTRK3 chimeric tyrosine kinase requires c-Src. , 2007, Cancer research.

[46]  A. Ashworth,et al.  A mouse model of basal‐like breast carcinoma with metaplastic elements , 2007, The Journal of pathology.

[47]  Cheng Li,et al.  Adjusting batch effects in microarray expression data using empirical Bayes methods. , 2007, Biostatistics.

[48]  S. Naber,et al.  Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. , 2007, Cancer research.

[49]  Zhiyuan Hu,et al.  Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors , 2007, Genome Biology.

[50]  Jeffrey T. Chang,et al.  Oncogenic pathway signatures in human cancers as a guide to targeted therapies , 2006, Nature.

[51]  R. Glazer,et al.  Characterization of medroxyprogesterone and DMBA‐induced multilineage mammary tumors by gene expression profiling , 2005, Molecular carcinogenesis.

[52]  R. Cardiff,et al.  Gene expression profiling of neu-induced mammary tumors from transgenic mice reveals genetic and morphological similarities to ErbB2-expressing human breast cancers. , 2003, Cancer research.

[53]  R. Cardiff,et al.  Gene Expression Profiling of Neu-induced Mammary Tumors from Transgenic Mice Reveals Genetic and Morphological Similarities to ErbB 2-expressing Human Breast Cancers 1 , 2003 .

[54]  Robert D Cardiff,et al.  Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. , 2002, The American journal of pathology.

[55]  C. Arteaga,et al.  Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases , 2002 .

[56]  C. Arteaga,et al.  Blockade of TGF-beta inhibits mammary tumor cell viability, migration, and metastases. , 2002, The Journal of clinical investigation.

[57]  K. Broman,et al.  Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. , 2001, Cancer research.

[58]  V. Godfrey,et al.  Impact of ionizing radiation and genetic background on mammary tumorigenesis in p53-deficient mice. , 2001, Cancer research.

[59]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Cardiff,et al.  c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations , 2001, Nature Medicine.

[61]  M. Rudnicki,et al.  Amplification of the neu/erbB-2 oncogene in a mouse model of mammary tumorigenesis. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Callahan,et al.  MMTV-induced mammary tumorigenesis: gene discovery, progression to malignancy and cellular pathways , 2000, Oncogene.

[63]  R. Cardiff,et al.  The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting‡ , 2000, Oncogene.

[64]  Christian A. Rees,et al.  Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[66]  T. Ried,et al.  Amplification of Ki-ras and elevation of MAP kinase activity during mammary tumor progression in C3(1)/SV40 Tag transgenic mice , 1998, Oncogene.

[67]  L. Hennighausen,et al.  Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. , 1996, Cancer research.

[68]  R. Palmiter,et al.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice. , 1995, Cancer research.

[69]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[70]  R. Cardiff,et al.  Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. , 1994, Genes & development.

[71]  R. Cardiff,et al.  Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[72]  R. Cardiff,et al.  Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease , 1992, Molecular and cellular biology.

[73]  S. Sukumar,et al.  Activation of H-ras oncogenes in preneoplastic mouse mammary tissues. , 1990, Oncogene.

[74]  W Godolphin,et al.  Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.

[75]  H. Varmus,et al.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice , 1988, Cell.

[76]  P. Leder,et al.  Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene , 1988, Cell.

[77]  W. McGuire,et al.  Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.

[78]  Harold E. Varmus,et al.  Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome , 1982, Cell.